12.09.2016 • NewsDede WillamsBayerMonsanto

Bayer to Divest Dermatology Arm?

As it prepares to pay a higher price to acquire US agrochemicals giant Monsanto – if it comes to a deal at all  – Bayer is said to be exploring the sale of its dermatology business. Bayer is working with JPMorgan Chase & Co on the sale, which could bring in more than €1 billion, sources cited by the news agency Bloomberg said.

Analysts told Bloomberg the dermatology business, most of which was picked up in the 2006 aquisition of former Berlin-based drugmaker Schering, could attract interest from existing manufacturers of skincare products including Nestle’s, Allergan and Almirall as well as private equity firms, Bloomberg’s sources suggested. 

Since announcing plans to acquire Monsanto, observers have also mooted that the Germany-based group could also shed its animal health business.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.